NASDAQ · JBIO
Jade Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for JBIO: Nov 12, 2026
Jade Biosciences, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.73. The reported EPS for the same quarter last year was $-0.48.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.73 | $-0.57 | $-0.83 | 5 |
| Dec 2026 | $-0.74 | $-0.52 | $-0.85 | 5 |
| Mar 2027 | $-0.74 | $-0.53 | $-0.90 | 3 |
| Jun 2027 | $-0.76 | $-0.54 | $-0.93 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Fintel- RTTNews · Sep 30, 9:28 AM EDTJade Biosciences Advances JADE301 Toward Phase 1 Trial In Dermatomyositis(RTTNews) – Jade Biosciences, Inc. (JBIO) is preparing to move JADE301 into human testing after preclinical studies showed the investigational antibody could selectively block IFN-Beta, a signaling protein believed to play an important role in dermatomyositis.
- RTTNews · Sep 30, 8:16 AM EDTJade Bioscience Reports Preclinical Data For JADE301(RTTNews) – Jade Biosciences, Inc. (JBIO) announced preclinical data for JADE301, an investigational, anti-IFN-Beta monoclonal antibody being developed for dermatomyositis, a rare autoimmune disease that can cause skin inflammation and muscle weakness.
- RTTNews · Aug 10, 10:32 AM EDTJade Reports Wider Loss In Q2, Expects Autoimmune Pipeline Interim Data In FY27(RTTNews) – Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, reported a wider net loss for the second quarter ended June 30, 2026, primarily reflecting research and development expenses that more than doubled from
- RTTNews · Jun 26, 12:04 PM EDTJade Biosciences Appoints Mark Eisner To The Board Of Directors(RTTNews) – Jade Biosciences, Inc. (JBIO) announced the appointment of Mark Eisner to its Board of Directors, effective June 25, 2026.
- RTTNews · Jun 23, 11:13 PM EDTTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment(RTTNews) – Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached
- RTTNews · Jun 4, 1:01 AM EDTJade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down(RTTNews) – Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company, priced a public offering of 10 million shares at $15.00 per share. The gross proceeds to Jade from the offering are expected to be $150.0 million.
- MarketBeat · Jun 1, 9:07 PM EDTJade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsJade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy. Chief Executive Officer Tom Fro
- RTTNews · May 27, 5:50 AM EDTJade Doses First Participant In JUNIPER Phase 2 Trial Of JADE 101 In IgA Nephropathy(RTTNews) – Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, on Tuesday announced that its first participant has been dosed in the JUNIPER Phase 2 study to evaluate JADE 101 in individuals with immunogl
- Fintel · Apr 9, 6:52 AM EDTJade Biosciences (JBIO) Price Target Increased by 10.24% to 28.82The average one-year price target for Jade Biosciences (NasdaqCM:JBIO) has been revised to $28.82 / share. This is an increase of 10.24% from the prior estimate of $26.14 dated March 25, 2026. The price target is an average of many targets provided by analysts
- Fintel · Mar 27, 10:48 AM EDTJade Biosciences (JBIO) Price Target Increased by 16.48% to 26.14The average one-year price target for Jade Biosciences (NasdaqCM:JBIO) has been revised to $26.14 / share. This is an increase of 16.48% from the prior estimate of $22.44 dated February 21, 2026. The price target is an average of many targets provided by analy
- Fintel · Jan 7, 7:03 AM ESTHC Wainwright & Co. Initiates Coverage of Jade Biosciences (JBIO) with Buy RecommendationFintel reports that on January 7, 2026, HC Wainwright & Co. initiated coverage of Jade Biosciences (NasdaqCM:JBIO) with a Buy recommendation. Analyst Price Forecast Suggests 60.06% Upside
- RTTNews · Jan 5, 9:02 AM ESTJade Biosciences To Report Phase I Trial Of JADE101 In 1H2026(RTTNews) – Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.P. Morgan Healthcare Conference taking plac
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Jade Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.